| rademikibart (CBP-201) / Suzhou Connect Biopharma |
| Not yet recruiting | 3 | 418 | RoW | SIM0718 injection, SIM0718 injection of placebo | Simcere Pharmaceutical Co., Ltd | Asthma; Eosinophilic | 06/27 | 09/27 | | |
NCT06477835: A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 250 | NA | SIM0718 Injection | Simcere Pharmaceutical Co., Ltd | Atopic Dermatitis | 08/25 | 07/26 | | |
NCT05017480: A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China |
|
|
| Completed | 2 | 330 | RoW | CBP-201, Placebo | Suzhou Connect Biopharmaceuticals, Ltd. | Moderate-to-severe Atopic Dermatitis | 12/22 | 09/23 | | |
|
| Completed | 2 | 322 | Europe, US, RoW | CBP-201, rademikibart, Placebo | Suzhou Connect Biopharmaceuticals, Ltd. | Moderate to Severe Persistent Asthma | 08/23 | 09/23 | | |
|
|
NCT05905133: A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD |
|
|
| Active, not recruiting | 2 | 360 | RoW | CBP-201, CBP-201 injection | Suzhou Connect Biopharmaceuticals, Ltd. | Atopic Dermatitis | 06/24 | 06/24 | | |
ACTRN12618000756224: Safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-201 in healthy volunteers
|
|
|
| Active, not recruiting | 1 | 40 | | | Connect Biopharma Australia Pty Ltd , Connect Biopharma Australia Pty Ltd | Atopic Dermatitis | | | | |
NCT05917782: A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects |
|
|
| Completed | 1 | 324 | RoW | Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL), Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL), Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL) | Suzhou Connect Biopharmaceuticals, Ltd. | Healthy Adult Subjects | 10/23 | 10/23 | | |
